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abstract
PURPOSE APHINITY, at 45 months median follow-up, showed that pertuzumab added to adjuvant trastuzumab
and chemotherapy significantly improved invasive disease–free survival (IDFS) (hazard ratio 0.81 [95% CI, 0.66
to 1.00], P 5 .045) for patients with early human epidermal growth factor receptor 2 (HER2)–positive breast
cancer (BC), specifically those with node-positive or hormone receptor (HR)–negative disease. We now report
the preplanned second interim overall survival (OS) and descriptive updated IDFS analysis with 74 months
median follow-up.
METHODS After surgery and central HER2-positive confirmation, 4,805 patients with node-positive or high-risk
node-negative BC were randomly assigned (1:1) to either 1-year pertuzumab or placebo added to standard
adjuvant chemotherapy and 1-year trastuzumab.
RESULTS This interim OS analysis comparing pertuzumab versus placebo did not reach the P 5 .0012 level
required for statistical significance (P 5 .17, hazard ratio 0.85). Six-year OS were 95% versus 94% with 125
deaths (5.2%) versus 147 (6.1%), respectively. IDFS analysis based on 508 events (intent-to-treat population)
showed a hazard ratio of 0.76 (95% CI, 0.64 to 0.91) and 6-year IDFS of 91% and 88% for pertuzumab and
placebo groups, respectively. The node-positive cohort continues to derive clear IDFS benefit from pertuzumab
(hazard ratio 0.72 [95% CI, 0.59 to 0.87]), 6-year IDFS being 88% and 83%, respectively. Benefit was not seen
in the node-negative cohort. In a subset analysis, IDFS benefit from pertuzumab showed a hazard ratio of 0.73
(95% CI, 0.59 to 0.92) for HR-positive disease and a hazard ratio of 0.83 (95% CI, 0.63 to 1.10) for HR-negative
disease. Primary cardiac events remain , 1% in both the treatment groups. No new safety signals were seen.
CONCLUSION This analysis confirms the IDFS benefit from adding pertuzumab to standard adjuvant therapy for
patients with node-positive HER2-positive early BC. Longer follow-up is needed to fully assess OS benefit.
J Clin Oncol 39:1448-1457. © 2021 by American Society of Clinical Oncology
INTRODUCTION
The human epidermal growth factor receptor 2
(HER2) is the second most important target for sys-
temic breast cancer (BC) therapy after the estrogen
receptor. HER2 overexpression is found in 15%-20%
of patients with BC. Today, HER2-directed therapies
are considered standard of care in the advanced- and
early-disease settings.1–3 Trastuzumab when added to
chemotherapy has shown improvement in overall
survival (OS) in patients with advanced and early
HER2-positive BC.4–7
Interest in dual HER2 blockade grew rapidly in view of
the improvement in OS seen in the advanced disease
and improvements in pathological complete response
rates in several neoadjuvant trials.8–14 Pertuzumab
plus trastuzumab and taxane is now considered the
standard first-line treatment for patients with advanced
disease and as part of a neoadjuvant regimen for
patients in high-risk subgroups.9,12
In the adjuvant setting, the approval of pertuzumab in
combination with trastuzumab and chemotherapy was
based on the primary analysis of APHINITY, which
showed an improved invasive disease–free survival
(IDFS) hazard ratio of 0.81 (95% CI, 0.66 to 1.00,
P 5 .045; 0.9% difference in 3-year IDFS percent) in
favor of the dual HER2 blockade strategy.15 Cardiac
events were infrequent in both the treatment groups
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the pertuzumab group than with placebo. The benefit
appeared more pronounced in patients at higher risk of
relapse such as those with node-positive disease, with a
hazard ratio of 0.77 (95% CI, 0.62 to 0.96; 3-year IDFS
92% v 90%), and in those with hormone receptor (HR)–
negative disease for whom the hazard ratio was 0.76 (95%
CI, 0.56 to 1.04; 3-year IDFS 93% v 91%). These results led
to regulatory approvals in several countries of pertuzumab
for patients at high risk of recurrence.
A first preplanned interim analysis for OS was performed at
the time of primary analysis (hazard ratio 0.89; 95% CI, 0.66
to 1.21, P 5 .47) with a median follow-up of 45 months. In
this paper, we report the results of the second, preplanned,
and time-driven interim analysis for OS as well as the
updated preplanned descriptive IDFS and safety results in
APHINITY with a median follow-up of 74 months.
METHODS
Study Design, Participants, Randomization, and Masking
APHINITY (BIG4-11;ClinicalTrials.gov identifier:NCT01358877)
is a randomized, placebo-controlled, phase III, double-
blind, multicenter trial. The full details of the trial
methods have been previously described.15 Briefly, 4,805
patients were recruited in 545 hospitals across 42 countries
between November 2011 and August 2013 after giving
informed consent. Eligible patients were randomly assigned
after adequate excision of a histologically confirmed in-
vasive HER2-positive BC (defined as a 3 1 immunohis-
tochemical score or amplification of the HER2 gene) to
chemotherapy plus either 1 year of trastuzumab and pla-
cebo or 1 year of trastuzumab and pertuzumab.16 Patients
were not eligible if they had received systemic neoadjuvant
therapy.
A Web-based system was used to collect patient screening
information and to randomly assign eligible patients in a 1:1
ratio to one of the two treatment groups. A permuted blocks
randomization procedure was used. Stratification factors
included nodal status, adjuvant chemotherapy regimen,
HR status, geographical region, and Protocol version
(onlline only). Patients with high-risk node-negative tumors
were initially eligible if they had tumors . 1 cm or between
0.5 and 1.0 cm and histological or nuclear grade 3 disease,
HR-negative disease, or age , 35. There were 3,655
patients randomly assigned worldwide under this version of
the Protocol. Under a Protocol amendment (Protocol B),
patients with node-negative disease were excluded. Of
note, eligibility criteria included a baseline left ventricular
ejection fraction (LVEF) of$ 55%. Patients with preexisting
cardiac conditions were excluded from the trial. Radio-
therapy was given as per local or national guidelines after
chemotherapy and concomitantly with anti-HER2 treat-
ment. Patients with HR-positive tumors received at least
5 years of standard endocrine therapy per local guidelines.
Procedures
Trastuzumab was given with a loading dose of 8 mg/kg of
body weight intravenously then at 6 mg/kg once every
3 weeks for 1 year (corresponding to 18 cycles). Patients
assigned to the pertuzumab group received a loading fixed
dose of 840 mg intravenously, then a fixed dose of 420 mg
once every 3 weeks for 1 year.
Investigators were allowed to choose between two types of
chemotherapy regimen, with anti-HER2 therapy started
concomitantly with the first taxane administration, either a
sequential anthracycline-taxane regimen or 3-weekly
docetaxel plus carboplatin (ie, with no anthracycline) 3
six cycles (Data Supplement, online only).
Details on clinical follow-up have previously been reported;
importantly, cardiac monitoring including measurement of
LVEF by multi-gated acquisition scanning or echocardi-
ography was performed every 3 months during treatment,
every 6 months up to month 36, and yearly thereafter.
Investigators collected data about any BC recurrence,
contralateral BC, and second primaries (nonbreast) in
CONTEXT
Key Objective
To provide updates on the efficacy and safety of adjuvant pertuzumab, trastuzumab, and chemotherapy after 6 years
median follow-up.
Knowledge Generated
The second interim analysis of overall survival in APHINITY did not show statistically significant benefit but data are still
immature at this time. Statistically significant improvement in invasive disease–free survival for patients with node-
positive, human epidermal growth factor receptor 2 (HER2)–positive early breast cancer was reinforced and cardiac
safety was confirmed with longer follow-up after adjuvant dual anti-HER2 treatment.
Relevance
The longer-term magnitude of benefit of adding pertuzumab to standard adjuvant therapy may not depend upon hormone
receptor status of the primary tumor. At this time, there is no evidence to justify the routine use of dual anti-HER2
treatment for patients with node-negative early breast cancer.
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addition to European Organisation for Research and
Treatment of Cancer Quality of Life C30 questionnaires. Any
cardiac event had to be classified into a primary or a
secondary event and was reviewed by a cardiac advisory
board, as reported previously.12 Patients are being followed
annually for disease relapse and vital status until 10 years
after random allocation of the last patient.
Outcomes
This analysis is a preplanned efficacy and safety analysis of
APHINITY, based on a time-driven second interim OS
analysis, and provides descriptive updates of IDFS from the
intent-to-treat (ITT) population and in relevant subgroups
as well as updates on cardiac safety.
Definitions of all end points were provided in the primary
analysis paper. Of note, the primary end point IDFS used in
APHINITY differs from the STEEP definition as it excludes
second primary non-BCs as events. It includes ipsilateral
invasive BC recurrence, locoregional invasive BC recur-
rence, contralateral invasive BC, distant recurrence, and
death because of any cause.15,17
Statistical Analysis
The first interim OS analysis took place at the time of
primary IDFS analysis. Two subsequent time-driven interim
analyses were planned with a final event-driven OS analysis
planned after 640 deaths have occurred. Here, we report
the second interim OS analysis, with a clinical cutoff date of
June 19, 2019, 2.5 years after the primary analysis. The
stratified log-rank test was used to compare OS percents
between the two treatment groups; a two-sided P value
, .0012 was required for statistical significance to control
the overall alpha level at 0.05. The Kaplan-Meier approach
was used to estimate 6-year percentages for each group.
The stratified Cox proportional-hazards model was used to
estimate hazard ratios and their 95% CIs. The strata for
efficacy analysis are nodal status, Protocol version, central
HR status, and adjuvant chemotherapy regimen. Region
is not considered in the stratified log-rank test. We es-
timated the standard errors and 95% CIs for the Kaplan-
Meier estimates according to the Greenwood formula.
The analysis was based on the ITT population. Updated
descriptive IDFS results were based on 508 events.
Descriptive analyses of IDFS in the overall ITT pop-
ulation and in key demographic subgroups were pre-
planned to be performed at the time of the interim OS
analyses.
Patients who received at least one dose of study treatment
were included in the safety analysis, according to the
treatment given. Primary cardiac events included heart
failure or cardiac death; secondary cardiac events included
asymptomatic or mildly symptomatic LVEF decrease.15
Role of the Funding Source
F. Hoffmann-La Roche/Genentech was the study sponsor.
APHINITY was designed by the Breast International Group
(BIG) in collaboration with the sponsor. Study conduct was
overseen by the joint study management team (composed
of representatives of the sponsor, BIG headquarters, and
independent data management and statistical centers) and
a cardiac advisory board under the auspices of BIG. The
trial involved the collaboration of 23 BIG groups, all of which
were represented in the Steering Committee of APHINITY,
which also included patient advocates, joint study man-
agement team members, and the cardiac advisory board.
The APHINITY Steering Committee had final responsibility
for the content of the paper.
The database was maintained at the Institut Jules Bordet
Clinical Trials Support Unit (Brussels, Belgium), and the
statistical analyses were carried out by Frontier Science
(Kincraig, UK; Boston, MA).
The sponsor provided study drug, site monitoring, and fi-
nancial support.
RESULTS
A CONSORT diagram is shown in Figure 1, and the trial
schema is presented in the Data Supplement. The ITT
analysis comprises all randomly assigned patients except
one who was excluded from the placebo group because
she had falsified personal information.
Patient Demographics
As shown in Table 1, the two treatment groups were
generally well-balanced. Further details on patient char-
acteristics have been described previously.15 The study had
63% of patients with axillary node-positive disease, 36%
had HR-negative tumors, and 78% received anthracycline-
based adjuvant chemotherapy.
With a median follow-up of 74 months (range 0-89), this
interim analysis of single versus dual HER2 blockade is
based on 508 IDFS events and 272 deaths (127 more
IDFS events and 103 more deaths than at the primary
analysis).
OS
Figure 2 shows OS in the ITT population. The two-sided
P value of .0012 required for statistical significance at this
second interim analysis of OS was not reached (hazard ratio
0.85 [95% CI, 0.67 to 1.07; P5 .17]). Six-year OS percents
were 95% and 94% and the number of deaths were 125
(5.2%) and 147 (6.1%) for the pertuzumab and placebo
groups, respectively.
IDFS
IDFS in the ITT population is shown in Figure 3. Consistent
with the primary analysis, the present results continue to
show fewer IDFS events in the pertuzumab group com-
pared with the placebo group (221 [9.2%] and 287
[11.9%], respectively) (hazard ratio 0.76; 95% CI, 0.64 to
0.91). At 6 years from randomization, 91% of patients in the
pertuzumab group and 88% of patients in the placebo
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group remain event-free, corresponding to an absolute
benefit of 2.8% (95% CI, 1.0 to 4.6).
The majority of first IDFS events were distant relapses, with
fewer distant relapses in the pertuzumab group (141
[5.9%]) than in the placebo group (184 [7.7%]). The
frequency of locoregional recurrence in the pertuzumab
group was 1.2%, compared with 2.0% in the placebo
group. No differences were seen in the occurrence of CNS
metastases (2.0% in each group) and contralateral BC
(close to 0.6% in each group) (Table 2). Distant recur-
rences with pertuzumab in the node-positive cohort oc-
curred in 8.3% of patients, compared with 11.1% in the
placebo group. The number of distant recurrences was low
in the node-negative cohort (17 in both the groups) (Data
Supplement).
IDFS by Subgroup
With 2.5 additional years of follow-up, a significant reduction
in IDFS events continues to be seen in the node-positive
cohort, with 173 events (11.5%) in the pertuzumab group
versus 239 events (15.9%) in the placebo group. The hazard
ratio was 0.72 (95% CI, 0.59 to 0.87), and the 6-year IDFS
was 88% in the pertuzumab group compared with 83% in
the placebo group, corresponding to an absolute benefit of
4.5% (95% CI, 1.9 to 7.1) (Fig 4A). There was, however, no
apparent benefit from the addition of pertuzumab in the
node-negative cohort, with 95% of patients in both the
groups event-free at 6 years after randomization (Fig 4B).
The HR-positive cohort, with additional follow-up (Fig 4D),
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FIG 1. CONSORT diagram for the APHINITY trial. *One patient excluded from the ITT population because of her falsification of personal information.
Study treatment includes chemotherapy, trastuzumab, and pertuzumab or placebo. See the Data Supplement for a complete APHINITY trial schema
including treatment details. Type of anthracycline-containing chemotherapy is summarized in Table 1. ITT, intent-to-treat.
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from pertuzumab with 131 (8.5%) IDFS events compared with
181 (11.7%) in the placebo group and a hazard ratio of 0.73
(95% CI, 0.59 to 0.92). At 6 years from randomization, IDFS
were 91% and 88%, respectively, with an absolute benefit of
3.0% (95% CI, 0.8 to 5.2). The HR-negative cohort shows
numerically fewer IDFS events in the pertuzumab group as
compared with the placebo group (90 [10.4%] v 106 [12.4%],
hazard ratio 0.83, 95% CI, 0.63 to 1.10).
IDFS results at the primary and updated analysis are sum-
marized in the Data Supplement. As in the primary analysis,
exploratory tests for interaction across all clinically relevant
subgroups have been performed for this updated analysis, all
of which were not statistically significant (Data Supplement).
Safety
Table 3 shows an update of cardiac safety. With 2.5 ad-
ditional years of follow-up, there has been one further
primary cardiac event (heart failure) in the pertuzumab
group and one further secondary cardiac event in each
group. Overall, the incidence of primary cardiac events
remains low at 0.8% in the pertuzumab group and 0.3% in
the placebo group. The incidence of secondary cardiac
events was 2.7% in the pertuzumab group and 2.8% in the
TABLE 1. Demographic and Baseline Disease Characteristics
Characteristic Pertuzumab (n 5 2,400) Placebo (n 5 2,404)
Nodal status
0 positive and tumor # 1 cma 90 (3.8%) 84 (3.5%)
0 positive nodes and tumor . 1 cma 807 (33.6%) 818 (34.0%)
1-3 positive nodes 907 (37.8%) 900 (37.4%)
$ 4 positive nodes 596 (24.8%) 602 (25.0%)
Adjuvant chemotherapy regimenb
Anthracycline-containing regimen 1865 (77.7%) 1877 (78.1%)
Epirubicin → docetaxel 1,054 (43.9%) 1,026 (42.7%)
Doxorubicin → docetaxel 245 (10.2%) 258 (10.7%)
Epirubicin → paclitaxel 276 (11.5%) 272 (11.3%)
Doxorubicin → paclitaxel 290 (12.1%) 321 (13.4%)
Non–anthracycline-containing regimen 535 (22.3%) 527 (21.9%)
Hormone receptor statusc
Negative 864 (36.0%) 858 (35.7%)
Positive 1,536 (64.0%) 1,546 (64.3%)
Protocol versiona
Protocol A 1828 (76.2%) 1827 (76.0%)
Protocol B 572 (23.8%) 577 (24.0%)
Age (years)
, 40 326 (13.6%) 327 (13.6%)
40-64 1759 (73.3%) 1784 (74.2%)
$ 65 315 (13.1%) 293 (12.2%)
Pathological tumor size, No. of tumors (%)d n 5 2,400 n 5 2,405
0 to , 2 cm 978 (40.8%) 948 (39.4%)
2-5 cm 1,275 (53.1%) 1,283 (53.3%)
$ 5 cm 147 (6.1%) 174 (7.2%)
aUnder the original Protocol (Protocol A), patients with node-negative tumors were initially eligible for participation in the trial if at least one of the following
high-risk features was present: histologic or nuclear grade 3, negativity for estrogen and progesterone receptors, or age ,35 years. Under a Protocol
amendment (Protocol B), patients with node-negative disease were no longer eligible for enrollment.
bThe chemotherapy regimen that was planned at the time of randomization is shown; the regimen that patients received may have differed.
cHormone receptor status was based on the test results determined by a central laboratory, which repeated the testing that was performed locally at each
participating center. Negative denotes estrogen receptor–negative and progesterone receptor–negative; positive denotes estrogen receptor–positive,
progesterone receptor–positive, or both.
dPatients with bilateral tumors have pathological characteristics reported for both tumors; therefore, pathological tumor characteristics are summarized at
the tumor level. There were seven patients with bilateral cancer where a pathological tumor size for a left-side tumor and for a right-side tumor was recorded.
There were 4,805 tumors summarized among 4,798 patients. There were six patients with no known pathological tumor size.
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placebo group. There were two fatal adverse events related
to a cardiac disorder in the pertuzumab group and four in
the placebo group (Table 3).
DISCUSSION
This second time-driven preplanned analysis of APHINITY
has confirmed improved IDFS with the addition of pertu-
zumab to chemotherapy plus trastuzumab for patients with
node-positive disease irrespective of HR status. The OS
analysis does not demonstrate significant impact of per-
tuzumab on mortality. OS data are immature at this point.
Only 42.5% of the 640 deaths required for the final analysis
have occurred. Therefore, patient follow-up is essential.
Of note, the 6-year OS percents are close to 95% for
patients on both the treatment groups although APHINITY
has a relatively high-risk population. These results further
reinforce the notion that the combination of HER2-
directed therapy and standard chemotherapy leads to
excellent outcomes in most patients with HER2-positive
early BC.
IDFS remains a valuable end point for adjuvant trials.18,19
With 2.5 years of additional follow-up, the evidence sup-
porting IDFS benefit at 74 months are strengthened in
comparison with the 45-month results and remain driven
by the node-positive cohort. In these patients with high-risk
disease, pertuzumab reduces the relative hazard of an
IDFS event by 28% and improves 6-year IDFS percent by
an estimated 4.5% (95% CI, 1.9 to 7.1). A reduction in
distant recurrences was seen in the node-positive cohort
(124 [8.3%] v 167 [11.1%]).
Updated results from this analysis strengthen the obser-
vation that patients with node-negative, HER2-positive early
BC show excellent IDFS results up to 6 years from diagnosis
when treated with standard adjuvant therapy without the
addition of pertuzumab. As shown in the forest plot in the
Data Supplement, the CI for this subgroup is wide and
includes the hazard ratio estimate for the node-positive
cohort. At this time, although a benefit for adding pertu-
zumab for patients with node-positive disease is clear, there
is no evidence to justify the routine use of dual anti-HER2
treatment for patients with node-negative early BC.
APHINITY probably signals the end of treatment escalation
for the node-negative subgroup and suggests that strate-
gies to reduce the burden of chemotherapy experienced by
these patients should be evaluated.20,21
The magnitude of benefit of pertuzumab may not depend
on HR status. We have learned through the long-term
follow-up of women with early BC that the HR-negative
population is at particularly high risk of relapse in the first 3
years, whereas events accumulate more slowly but con-
tinually in the HR-positive cohort.22,23 In APHINITY, the
absolute benefit of pertuzumab for IDFS at 6 years from
randomization is 2.5% (95% CI, 20.7 to 5.6) for the HR-
negative cohort and 3.0% (95% CI, 0.8 to 5.2) for the HR-
positive cohort. This is consistent with long-term benefits of
adjuvant trastuzumab, independent of HR status.7
Because no cardiac safety issues have emerged with ad-
ditional follow-up, the benefit-versus-harm ratio is en-
hanced with only one further primary cardiac event in the
pertuzumab group reported since the primary analysis.
Patient-reported outcomes in APHINITY have demon-
strated that other side effects seen in $ 1% of patients are
generally mild and do not impact global quality of life or
social functioning.24 The 6% increase in the risk of grade 3
or more diarrhea with pertuzumab reported in the primary
analysis (from 4% in the placebo arm v 10% in the per-
tuzumab arm) was indeed clinically relevant, but this side
effect occurred mostly while patients were on chemo-
therapy, particularly with docetaxel, and rapidly improved
when anti-HER2 therapies were given alone.24
There is evidence of a shift from adjuvant to neoadjuvant
therapy in clinical practice as a result of personalized
medicine, reducing the risk of both overtreatment and
undertreatment at the individual patient level.25 The
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Stratified HR (95% CI) 0.85 (0.67 to 1.07)
Six years from randomization
Difference in event-free rate (%)
95% CI for difference (–0.5 to 2.2)
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No. of patients at risk
2,404 2,339 2,292 2,241 2,165 2,107 1,522
2,400 2,304 2,261 2,216 2,161 2,090 1,544
FIG 2. Kaplan-Meier plot of overall survival (intent-to-treat pop-
ulation). FU, follow-up; HR, hazard ratio; OS, overall survival.
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Stratified HR (95% CI) 0.76 (0.64 to 0.91)
Six years from randomization
Difference in event-free rate (%)
95% CI for difference (1.0 to 4.6)
2.8





Median FU, months 74.1
2,404 2,312 2,215 2,134 2,039 1,967 1,421
2,400 2,277 2,198 2,122 2,055 1,978 1,482
FIG 3. Kaplan-Meier plot of IDFS (intent-to-treat population). FU,
follow-up; HR, hazard ratio; IDFS, invasive disease–free survival.
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possibility for salvage for patients with residual disease after
neoadjuvant treatment, as confirmed by the results of the
KATHERINE study, can potentially limit the usefulness of
intensive adjuvant treatments in the future at least in high-
resource settings where trastuzumab emtansine is already
accessible.25 However, not all regions have access to tras-
tuzumab emtansine and not all healthcare systems can
optimally monitor patients during neoadjuvant treatment.
Availability of effective adjuvant therapy will still be an im-
portant component of curative treatment in these settings.
TABLE 2. Site of First Invasive-Disease Eventa
Event Pertuzumab (n 5 2,400) Placebo (n 5 2,404)
Any invasive-disease event 221 (9.2%) 287 (11.9%)
Category of first invasive-disease event
Distant recurrence 141 (5.9%) 184 (7.7%)
CNS metastases 49 (2.0%) 49 (2.0%)
Locoregional recurrence 28 (1.2%) 49 (2.0%)
Contralateral breast cancer 13 (0.5%) 15 (0.6%)
Death without previous event 39 (1.6%) 39 (1.6%)
aPatients who had an additional invasive event within 61 days of their first event are reported in the category according to the following hierarchy: distant
recurrence, locoregional recurrence, contralateral breast cancer, and death without previous event.
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FIG 4. Kaplan-Meier plot of IDFS by subgroup, ITT population. IDFS in (A) the node-positive cohort, (B) the node-negative cohort, (C) the hormone
receptor–negative cohort, and (D) the hormone receptor–positive cohort. HR, hazard ratio; IDFS, invasive disease–free survival; ITT, intent-to-treat.
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A limitation of APHINITY is the reliance on a single,
pathologic biomarker of potential benefit from pertuzumab,
namely nodal status. As it is possible that other patient
subgroups may benefit, we plan to develop a composite
prognostic score that might help the clinicians identify
the most suitable patients for dual as opposed to single
HER2 blockade, in the same way it has contributed to
improved selection of premenopausal patients who may
benefit from suppression of ovarian function plus
exemestane, as opposed to tamoxifen in the SOFT and
TEXT trials.26–28
A remaining question is whether the 12-month duration of
pertuzumab is optimal. It is unclear whether shorter du-
rations of dual HER2 blockade will be further investigated,
given the many challenges raised by the five trials that were
designed to demonstrate noninferiority of 6 or 3 months of
adjuvant trastuzumab compared with the standard 12-
month duration.29–31
In conclusion, this second interim analysis of OS in the
APHINITY trial did not demonstrate a statistically significant
OS benefit from the addition of pertuzumab to standard
chemotherapy plus trastuzumab in HER2-positive early-
stage BC; the number of OS events to date remains rela-
tively low. The benefits of comprehensive HER2 blockade
using pertuzumab and trastuzumab in the adjuvant setting
for patients with node-positive disease observed at the pri-
mary analysis are reinforced in the updated analysis of IDFS.
Currently, there is no evidence to justify the routine use of
adjuvant dual anti-HER2 treatment for patients with node-
negative early BC. The longer-term benefit of pertuzumab
may not depend on the HR status of the primary tumor. No
cardiac safety concerns have emerged after a median follow-
up of 74 months. Continued follow-up of patients is im-
portant to fully assess OS benefit at the time-driven third
interim OS analysis planned for 2022 and the event-driven
final OS analysis planned when 640 deaths have occurred.
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21Gynäkologisch-Onkologische Praxis Hannover, Hannover, Germany
22Division of Medical Senology, IEO, European Institute of Oncology,
IRCCS, Milan, Italy
23Instituto Nacional de Câncer, Rio de Janeiro, Brazil
24Dana-Farber Cancer Institute, Harvard Medical School, Harvard TH
Chan School of Public Health, Frontier Science Foundation, Boston, MA
25University of Milan, IEO, European Institute of Oncology, IRCCS, Milan,
Italy
26Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany
TABLE 3. Summary of Adverse Events by Safety Analysis Population
Event Pertuzumab (n 5 2,364) Placebo (n 5 2,405)
Fatal adverse eventa 22 (0.9%) 30 (1.2%)
Primary cardiac eventb 18 (0.8%) 8 (0.3%)
Secondary cardiac eventc 65 (2.7%) 68 (2.8%)
Identified automatically from LVEF assessments 50 (2.1%) 47 (2.0%)
Identified by the cardiac advisory board 15 (0.6%) 21 (0.9%)
Abbreviation: LVEF, left ventricular ejection fraction.
aFor six of the patients, the fatal adverse event was a cardiac disorder—two (0.1%) in the pertuzumab group and four (0.2%) in the placebo group. For 30 of
the patients, the fatal adverse event was in the superclass term neoplasms benign, malignant, and unspecified—13 (0.5%) patients in the pertuzumab group
and 17 (0.7%) patients in the placebo arm. There was one pertuzumab patient with two fatal adverse events of a nervous system disorder.
bPrimary cardiac events are counted over the whole trial period, including post-treatment follow-up; one further primary cardiac event (heart failure) in the
pertuzumab arm since the primary analysis.
cSecondary cardiac events are counted up to the date of recurrence or the end of post-treatment follow-up, whichever occurs earlier, and are counted only
for patients who have not had a primary cardiac event; one further patient with secondary cardiac event in each arm since the primary analysis.
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